X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Medicare Monday: How Part B has evolved over the years

By Nicole Longo  |    July 24, 2017
With Medicare’s birthday rapidly approaching (July 30!), today we’re highlighting a few of the ways reimbursement for physician-administered medicines under Part B has changed since it was first...   Read More

Policy conditions make or break leaders in biopharmaceutical innovation: Preliminary results from the 2017 BCI Survey

By Meir Pugatch  |    July 24, 2017
In a world of global investment flows, securing a larger portion of the $150 billion invested per year by the research-based biopharmaceutical industry is anyone’s game. The 2017 results of the...   Read More

New PhRMA resources chock full of biopharma industry facts

By John Corea  |    July 20, 2017
Did you know that PhRMA member companies invested $65.5 billion in research and development (R&D) in 2016? Or that combined spending on brand medicines, generics and the supply chain account for...   Read More

New video: Patient and researcher fight JRA together

By Amber Lyons  |    July 19, 2017
Have you ever heard of juvenile rheumatoid arthritis (JRA)? A lot of people haven’t.   Read More

New report portrays flourishing pipeline

By Gretta Stone  |    July 18, 2017
It’s an exciting time to be working in the biopharmaceutical industry. Almost every day new headlines highlight remarkable new advances in the fight against disease. Some have called this the...   Read More

Medicare Monday: What you need to know about the latest Medicare Trustees report

By Nicole Longo  |    July 17, 2017
Last week, the Trustees of the Social Security and Medicare trust funds released its annual report on the current and projected financial status of Medicare. Here are a few important takeaways in...   Read More

340B Spotlight: New analysis finds 340B program growth continues to accelerate despite false claims

By Nicole Longo  |    July 13, 2017
This week, Berkeley Research Group (BRG) released a new whitepaper pushing back on the highly misleading claim that 340B sales are only 2 percent of annual U.S. drug sales. Citing a number of...   Read More

Why reauthorization of PDUFA matters

By Andrew Powaleny  |    July 13, 2017
Last night, the Prescription Drug User Fee Act (PDUFA), was reauthorized by the House of Representatives. PDUFA provides the U.S. Food and Drug Administration (FDA) with necessary resources to...   Read More

New “Let’s Talk About Cost” campaign convenes national dialogue on medicine costs

By Robert Zirkelbach  |    July 12, 2017
Discussions about costs are important. We recognize that many are struggling to access the medicine they need and have important questions about their medicine costs. And we want to help find the...   Read More

Going boldly together: New advancements and new anniversaries

By Amber Lyons  |    July 11, 2017
Hopefully you’ve had the chance to meet Salim and Roxanne from our Together series on GoBoldly.com. Salim is an antirejection researcher and Roxanne had a heart transplant 7 years ago this week...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates